(2025)
Treatment of complicated gram-positive bacteremia and infective endocarditis.
Drugs 85(2),
193-214.
(Review)
Dr.med. Paul Schellong
Translational Infection Medicine · Scientific Coworker Paul.Schellong@leibniz-hki.deCurriculum vitae
Professional Career
| Since 2023 | Postdoctoral researcher, Leibniz Institute for Natural Product Research and Infection Biology—Hans Knöll Institute; Head: Prof. Dr. Sebastian Weis |
| Since 2022 | Resident Physician Internal Medicine/Infectious Diseases, Institute of Infectious Diseases and Infection Control, University Hospital Jena, Germany, Head: Prof. Dr. Mathias W. Pletz |
| 2020 – 2022 | Resident Physician Internal Medicine (Cardiology and Intensive Care), Department of Internal Medicine III, University Hospital Halle (Saale), Germany, Head: Prof. Dr. Daniel G. Sedding |
| 2022 | Medical Dissertation “Biomarkers for mortality prediction in infarction-related cardiogenic shock” (summa cum laude), University of Leipzig, Germany, Supervision: Prof. Dr. Uta Ceglarek |
| 2012 – 2020 | Medical school, Leipzig University, Leipzig, Germany, Licensed physician (MD) |
Awards · Appointments · Scientific Activities
Scholarships:
| 2017-2018 | Dissertation scholarship of the Medical Faculty, Leipzig University |
Publications
(2024)
Long versus short course anti-microbial therapy of uncomplicated Staphylococcus aureus bacteraemia: a systematic review.
Clin Microbiol Infect 30(10),
1254-1260.
(2022)
Behandlung von Staphylococcus-aureus-Blutstrominfektionen.
Z Pneumologie 19,
343-358.
(2021)
The novel cystatin C, lactate, interleukin-6, and N-terminal pro-B-type natriuretic peptide (CLIP)-based mortality risk score in cardiogenic shock after acute myocardial infarction.
Eur Heart J 42(24),
2344-2352.
(2021)
Association of plasma trimethylamine N-oxide levels with atherosclerotic cardiovascular disease and factors of the metabolic syndrome.
Atherosclerosis 335,
62-67.